Hermans Kate 4

4 · Ambrx Biopharma Inc. · Filed Jan 31, 2023

Form 4

Period: 2023-01-27

Director

Transactions

Disposition to Issuer
Stock Option (right to buy)
2023-01-27−210,000→ 0 total
Exercise: $0.38Exp: 2032-06-29→ Ordinary Shares (210,000 underlying)
Award
Stock Option (right to buy)
2023-01-27+210,000→ 210,000 total
Exercise: $0.28Exp: 2032-06-29→ Ordinary Shares (210,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-01-27−105,000→ 0 total
Exercise: $0.43Exp: 2032-07-07→ Ordinary Shares (105,000 underlying)
Award
Stock Option (right to buy)
2023-01-27+105,000→ 105,000 total
Exercise: $0.28Exp: 2032-07-07→ Ordinary Shares (105,000 underlying)
Disposition to Issuer
Stock Option (right to buy)
2023-01-27−210,000→ 0 total
Exercise: $0.35From: 2022-12-15Exp: 2032-08-14→ Ordinary Shares (210,000 underlying)
Award
Stock Option (right to buy)
2023-01-27+210,000→ 210,000 total
Exercise: $0.28From: 2022-12-15Exp: 2032-08-14→ Ordinary Shares (210,000 underlying)

Footnotes (4)

[F1]The Ordinary Shares subject to the option vest in thirty-six equal monthly installments following June 30, 2022.
[F2]The Ordinary Shares of the Issuer may be represented by American Depositary Shares ("ADSs"). Each ADS represents seven Ordinary Shares of the Issuer.
[F3]The option held by the reporting person was amended to reduce the exercise price.
[F4]The Ordinary Shares subject to the option will vest on the earlier of (i) July 8, 2023, or (ii) the day immediately prior to the date of the next Annual Grant Date as defined in the Company's Non-Employee Director Compensation Policy.

Documents

1 file